---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-055770"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:35:11.265743+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q1 2023: net income $45.7M ($0.30 EPS); LINZESS demand up 10% YoY

## Summary
- Total revenues $104.1M, up 7% YoY; GAAP net income $45.7M vs $38.8M.
- LINZESS U.S. net sales $250M (+8% YoY); prescription demand grew 10% YoY.
- Ended Q1 with $740M cash; full-year 2023 financial guidance maintained.
- PDUFA date June 14 for potential pediatric functional constipation indication in ages 6-17.

## SEC filing metadata
- accession: 0001104659-23-055770
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/0001104659-23-055770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/tm2314422d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-055770
- JSON: https://secwatch.observer/filing/0001104659-23-055770.json
- Plain text: https://secwatch.observer/filing/0001104659-23-055770.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported first quarter 2023 results: revenue $ 104,061, net income 45,714, EPS 0.30. Guidance reaffirmed.
  - Period: first quarter 2023
  - Revenue: $ 104,061
  - Net income: 45,714
  - EPS: 0.30
  - Guidance: reaffirmed
  - Result: reported results
  source text: supporting the next growth horizon for the company.” First Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 1Q 2023 1Q 2022 Total revenues $ 104,061 $ 97,529 Total operating expenses 43,964 39,683 GAAP net income 45,714 38,801 GAAP net income per share – basic 0.30 0.25 GAAP net income per share –diluted 0.25 0.21 Adjusted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/0001104659-23-055770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.